Paul Moss

1 month ago | nature.com | Paul Moss

Virus-specific T cells within the mucosa mediate local defense and establish tissue-resident memory. Strong and functional mucosal SARS-CoV-2-specific responses associate with viral clearance and their effective induction is an important aspiration for vaccine regimens.

Jul 8, 2024 | nature.com | Emma Copland |Defne Saatci |Nicholas L. Mills |Paul Moss |Aziz Sheikh |Chris Robertson

Correction to: Nature Communications https://doi.org/10.1038/s41467-024-47745-z, published online 27 May 2024The original version of this article contained information on vaccine dose amount (full or half) in Table 2 and Supplementary Table 1. This has subsequently been found to be inaccurate due to inconsistent coding in the raw data. The vaccine dose amount has therefore been removed from Table 2 and Supplementary Table 1. This data was not used elsewhere in the analysis.

Jun 13, 2024 | nature.com | Calum Macdonald |Norah E Palmateer |Laura Lindsay |Safraj Shahul Hameed |Karen Jeffrey |Luke Daines | +9 more

AbstractSeveral population-level studies have described individual clinical risk factors associated with suboptimal antibody responses following COVID-19 vaccination, but none have examined multimorbidity. Others have shown that suboptimal post-vaccination responses offer reduced protection to subsequent SARS-CoV-2 infection; however, the level of protection from COVID-19 hospitalisation/death remains unconfirmed.

Jun 13, 2024 | nature.com | Calum Macdonald |Norah E Palmateer |Laura Lindsay |Safraj Shahul Hameed |Karen Jeffrey |Luke Daines | +9 more

AbstractSeveral population-level studies have described individual clinical risk factors associated with suboptimal antibody responses following COVID-19 vaccination, but none have examined multimorbidity. Others have shown that suboptimal post-vaccination responses offer reduced protection to subsequent SARS-CoV-2 infection; however, the level of protection from COVID-19 hospitalisation/death remains unconfirmed.

May 27, 2024 | nature.com | Emma Copland |Defne Saatci |Nicholas L. Mills |Paul Moss |Aziz Sheikh |Chris Robertson

AbstractThe risk-benefit profile of COVID-19 vaccination in children remains uncertain. A self-controlled case-series study was conducted using linked data of 5.1 million children in England to compare risks of hospitalisation from vaccine safety outcomes after COVID-19 vaccination and infection. In 5-11-year-olds, we found no increased risks of adverse events 1–42 days following vaccination with BNT162b2, mRNA-1273 or ChAdOX1.